A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Imlunestrant|DRUG: Tamoxifen|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane
Sponsor: Eli Lilly and Company